We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.88%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.2B
AUM Growth
+$12M
Cap. Flow
-$165M
Cap. Flow %
-3.93%
Top 10 Hldgs %
34.34%
Holding
127
New
6
Increased
36
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$21.9M
2
BSX icon
Boston Scientific
BSX
+$14M
3
MRUS
Merus
MRUS
+$10.5M
4
AGL icon
Agilon Health
AGL
+$8.99M
5
BPMC
Blueprint Medicines
BPMC
+$8.35M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$111M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$40.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$25.9M
4
PEN icon
Penumbra
PEN
+$20.7M
5
UNH icon
UnitedHealth
UNH
+$19.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.12%
2 Consumer Staples 1.04%
3 Industrials 0.9%
4 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABCM
26
DELISTED
Abcam PLC
ABCM
$58.9M 1.4%
2,405,000
+162,500
+7% +$2.8M
PRTA icon
27
Prothena Corp
PRTA
$450M
$51.4M 1.22%
753,462
– –
HZNP
28
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$50.9M 1.21%
495,000
-245,100
-33% -$25.9M
SRPT icon
29
Sarepta Therapeutics
SRPT
$1.77B
$48.7M 1.16%
425,000
-17,500
-4% -$2.26M
MIRM icon
30
Mirum Pharmaceuticals
MIRM
$6.14B
$47.1M 1.12%
1,820,733
+25,000
+1% +$665K
MDGL icon
31
Madrigal Pharmaceuticals
MDGL
$11.8B
$46M 1.09%
199,218
-148,903
-43% -$40.3M
XENE icon
32
Xenon Pharmaceuticals
XENE
$6.12B
$45.4M 1.08%
1,178,002
– –
FRPT icon
33
Freshpet
FRPT
$3.22B
$43.6M 1.04%
662,500
– –
PCRX icon
34
Pacira BioSciences
PCRX
$997M
$41.5M 0.99%
1,035,000
+2,400
+0.2% +$99.2K
ACRS icon
35
Aclaris Therapeutics
ACRS
$869M
$41.1M 0.98%
3,961,849
– –
MRTX
36
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$40.5M 0.96%
1,121,647
+56,386
+5% +$2.32M
PHR icon
37
Phreesia
PHR
$773M
$40.5M 0.96%
1,305,000
+2,500
+0.2% +$78.3K
ACCD
38
DELISTED
Accolade Inc
ACCD
$38M 0.9%
2,820,000
+275,000
+11% +$3.57M
ASND icon
39
Ascendis Pharma A/S
ASND
$16.8B
$38M 0.9%
425,500
– –
KYMR icon
40
Kymera Therapeutics
KYMR
$8.94B
$34.2M 0.81%
1,487,551
+259,172
+21% +$7.43M
ZLAB icon
41
Zai Lab
ZLAB
$2.62B
$33.9M 0.81%
1,222,423
+162,723
+15% +$5.32M
AMLX icon
42
Amylyx Pharmaceuticals
AMLX
$2.54B
$33.3M 0.79%
1,544,616
+91,800
+6% +$2.48M
SWAV
43
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$32.9M 0.78%
115,100
– –
IRTC icon
44
iRhythm Holdings
IRTC
$4.2B
$32.3M 0.77%
309,450
– –
LEGN icon
45
Legend Biotech
LEGN
$4.01B
$31.6M 0.75%
458,265
– –
OLK
46
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$31M 0.74%
1,654,000
+4,000
+0.2% +$82.8K
NVRO
47
DELISTED
NEVRO CORP.
NVRO
$30.8M 0.73%
1,211,400
+133,500
+12% +$3.85M
IMTX icon
48
Immatics
IMTX
$1.32B
$29.3M 0.7%
2,536,144
+22,221
+0.9% +$207K
CNMD icon
49
CONMED
CNMD
$1.47B
$27.9M 0.66%
205,000
– –
XLV icon
50
State Street Health Care Select Sector SPDR ETF
XLV
$43.3B
$26.5M 0.63%
200,000
– –
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Rock Springs Capital Management held 127 positions worth $4.2B, up 0.29% from $4.19B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management withdrew a net $165M in Q2 2023, closing 4 positions and reducing 16 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $111M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Boston Scientific worth $14.5M.

  • Rock Springs Capital Management's largest Q2 2023 buy was Boston Scientific: 267,500 shares worth $14.5M.
  • Rock Springs Capital Management added most to Humana in Q2 2023, an estimated $21.9M increase.
  • Rock Springs Capital Management's biggest Q2 2023 reduction was Madrigal Pharmaceuticals, cutting an estimated $40.3M.
  • Rock Springs Capital Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $111M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $4.2B portfolio in Q2 2023.
  • Rock Springs Capital Management opened 6 new positions and closed 4 in Q2 2023.
  • Rock Springs Capital Management's portfolio value rose 0.29% quarter-over-quarter to $4.2B.

Based on Rock Springs Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.